IDH1/2 mutant gliomas—particularly those with more favorable histologic features—are associated with a greater survival than IDH1/2 wildtype GBM which is characterized by a median survival of approximately 15 months [87,88,89,90,91,92,93]. Here, IDH1 is linked to central nervous system cancer.